Table 3 ELABELA levels according to disease stage and tests in patients with CLL
From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Variables | CLL | ELABELA (ng/ml) | p |
|---|---|---|---|
STAGE | N = 42 | ||
0 | 7 (16.7) | 7.6 (6.2–19.6) | 0.361 |
1 | 16 (38.1) | 6.3 (0.6–19.7) | |
2 | 10 (23.8) | 6.3 (0.6–9.7) | |
3 | 6 (14.3) | 6.4 (0.7–15.8) | |
4 | 3 (7.1) | 4.8 (1.1–7.3) | |
DC | N = 42 | ||
Negative | 34 (81.0) | 7 (0.6–19.7) | 0.134 |
Positive | 5 (11.9) | 2.9 (0.7–6.9) | |
Weak positive | 3 (7.1) | 3 (1.1–19.6) | |
p53 | N = 21 | ||
Negative | 15 (71.4) | 7.6 (0.7–19.7) | 0.080 |
Positive | 6 (28.6) | 3.4 (0.6–8.8) | |
DEL13q | N = 14 | ||
Negative | 5 (35.7) | 6.2 (0.7–9.7) | 0.898 |
Positive | 9 (64.3) | 6.6 (0.6–16.4) |